← FDA DRUG APPROVALS
FDA NDA · NDA211875
PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND
paclitaxel
Sponsor: AM REGENT
APPLICATION
NDA211875
TYPE
NDA
ORIGINAL APPROVAL
2022-07-27
LATEST ACTION
2022-07-27
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
PACLITAXEL · ReferencePrescription
PACLITAXEL 100MG/VIAL · POWDER · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.